Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-11
2008-03-04
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S543000, C548S550000
Reexamination Certificate
active
07338975
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
REFERENCES:
patent: 6011052 (2000-01-01), Padia et al.
patent: 6706712 (2004-03-01), Cherney
patent: 2003/0060459 (2003-03-01), Cherney et al.
patent: 2003/0171218 (2003-09-01), Bojack et al.
patent: 2003/0216434 (2003-11-01), Cherney
patent: 2004/0110736 (2004-06-01), Cherney
patent: 2004/0235835 (2004-11-01), Carter
patent: 2004/0235836 (2004-11-01), Cherney
patent: 2005/0043392 (2005-02-01), Carter
patent: 761 680 (1997-03-01), None
patent: 10251295 (1998-09-01), None
patent: WO 9716425 (1997-05-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 99/07351 (1999-02-01), None
patent: WO 99/07678 (1999-02-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/40913 (1999-08-01), None
patent: WO 99/40914 (1999-08-01), None
patent: WO 9962904 (1999-12-01), None
patent: WO 9962904 (1999-12-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 0222572 (2002-03-01), None
patent: WO 02/50019 (2002-06-01), None
patent: WO 0250019 (2002-06-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/070523 (2002-09-01), None
patent: WO 03030899 (2003-04-01), None
patent: WO 03075853 (2003-09-01), None
patent: WO 2004071460 (2004-08-01), None
patent: WO 2004098512 (2004-11-01), None
patent: WO 2004098516 (2004-11-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews 1996, vol. 96, pp. 3147-3176.
U.S. Appl. No. 10/922,406, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/923,619, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/923,538, filed Aug. 19, 2004, Carter et al.
U.S. Appl. No. 10/776,828, filed Feb. 11, 2004, Cherney et al.
Cregge et al., “Inhibition of Human Neutrophil Elastase. 4. Design, Synthesis, X-ray Crystallographic Analysis, and Structure-Activity Relationships for a Series of P2-Modified, Orally Active Peptidyl Pentafluoroethyl Ketones”,J. Med Chem., vol. 41, pp. 2461-2480, 1998.
Carter Percy H.
Voss Matthew E.
Bristol-Myers Squibb Co.
Duncan Laurelee A.
Kosack Joseph R.
Vanatten Mary
LandOfFree
Lactams as modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactams as modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactams as modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3978916